OLEMA PHARMACEUTICALS, INC. (OLMA) Current Ratio
- Current ratio · latest quarter: Value 8.86×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 8.86× | Current assets / current liabilities. $469.88M ÷ $53.01M ≈ 8.86× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 469.88M USD | Assets, Current |
| Current obligations | 53.01M USD | Liabilities, Current |
| Cash and equivalents | 48.60M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 412.47M USD | Marketable Securities, Current |
| Customer receivables | (m) | |
| Inventory | (m) | |
| Payables | 1.67M USD | Accounts Payable, Current |
| Borrowing debt due within one year | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $469.88M | $53.01M | $48.60M | $412.47M | (m) | (m) | $1.67M | (m) | 8.86× |
| 2026-03-31 | $513.23M | $47.17M | $52.55M | $452.80M | (m) | (m) | $3.72M | (m) | 10.88× |
| 2025-12-31 | $515.45M | $51.80M | $48.30M | $457.14M | (m) | (m) | $9.25M | (m) | 9.95× |
| 2025-09-30 | $334.33M | $41.66M | $35.26M | $293.70M | (m) | (m) | $3.47M | (m) | 8.03× |
| 2025-06-30 | $367.73M | $33.16M | $52.47M | $309.44M | (m) | (m) | $934.00K | (m) | 11.09× |
| 2025-03-31 | $396.66M | $26.06M | $50.64M | $342.07M | (m) | (m) | $151.00K | (m) | 15.22× |
| 2024-12-31 | $438.47M | $41.76M | $139.48M | $294.61M | (m) | (m) | $4.46M | (m) | 10.50× |
| 2024-09-30 | $217.99M | $30.70M | $35.89M | $178.88M | (m) | (m) | $2.69M | (m) | 7.10× |
| 2024-06-30 | $242.19M | $26.54M | $16.89M | $222.21M | (m) | (m) | $4.35M | (m) | 9.13× |
| 2024-03-31 | $252.09M | $26.22M | $33.72M | $215.26M | (m) | (m) | $7.66M | (m) | 9.61× |
| 2023-12-31 | $266.51M | $21.62M | $68.54M | $193.27M | (m) | (m) | $2.70M | (m) | 12.33× |
| 2023-09-30 | $282.01M | $15.97M | $117.41M | $159.49M | (m) | (m) | $2.21M | (m) | 17.66× |
| 2023-06-30 | $171.51M | $14.83M | $34.96M | $132.49M | (m) | (m) | $1.63M | (m) | 11.56× |
| 2023-03-31 | $189.40M | $19.41M | $40.92M | $145.04M | (m) | (m) | $681.00K | (m) | 9.76× |
| 2022-12-31 | $208.90M | $16.55M | $23.70M | $180.72M | (m) | (m) | $374.00K | (m) | 12.62× |
| 2022-09-30 | $225.06M | $12.55M | $26.80M | $195.80M | (m) | (m) | $14.00K | (m) | 17.93× |
| 2022-06-30 | $243.03M | $12.31M | $24.53M | $216.19M | (m) | (m) | $120.00K | (m) | 19.75× |
| 2022-03-31 | $270.21M | $10.17M | $21.51M | $246.36M | (m) | (m) | $268.00K | (m) | 26.57× |
| 2021-12-31 | $290.69M | $9.02M | $13.81M | $273.44M | (m) | (m) | $23.00K | (m) | 32.23× |
| 2021-09-30 | $308.28M | $8.90M | $25.60M | $280.36M | (m) | (m) | $306.00K | (m) | 34.63× |
| 2021-06-30 | $320.85M | $8.15M | $50.42M | $267.72M | (m) | (m) | $385.00K | (m) | 39.39× |
| 2021-03-31 | $330.26M | $5.28M | $47.88M | $279.09M | (m) | (m) | $419.00K | (m) | 62.59× |
| 2020-12-31 | $342.14M | $4.58M | $338.55M | (m) | (m) | (m) | $719.00K | (m) | 74.62× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |